Marker Therapeutics, Inc.
MRKRMarker Therapeutics is a clinical-stage immuno-oncology company focused on developing non-genetically modified T cell-based immunotherapies for hematological malignancies and solid tumors.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
Profile
Marker Therapeutics is a clinical-stage immuno-oncology company focused on developing non-genetically modified T cell-based immunotherapies for hematological malignancies and solid tumors. The company's proprietary Multi Antigen Recognizing (MAR)-T cell technology selectively expands natural tumor-specific T cells to target multiple tumor-associated antigens simultaneously, aiming to reduce tumor escape and toxicity compared to traditional engineered cell therapies.
Marker differentiates itself by utilizing non-genetically engineered T cells that target up to six antigens, positioning its platform as a safer and more durable alternative to traditional CAR-T therapies.
Questions, answered.
- What is Marker Therapeutics, Inc.'s market cap?
- Marker Therapeutics, Inc. (MRKR) has a market capitalization of $20.3M and trades on NASDAQ.
- Who are Marker Therapeutics, Inc.'s competitors?
- Marker Therapeutics, Inc.'s key competitors include Gilead Sciences, Bristol-Myers Squibb, Cartesian Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Marker Therapeutics, Inc. partner with?
- Marker Therapeutics, Inc.'s notable partners include Baylor College of Medicine.
- Where is Marker Therapeutics, Inc. headquartered?
- Marker Therapeutics, Inc. is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 1998.